�Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) announced that the company has developed a gel-like form of Oxycyte� that it intends to investigate as a topical lotion for open wounds, abrasions and nathan Birnbaum. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic o carrier.
The innovation is based on technologies in-licensed earlier this year from Virginia Commonwealth University. In combination with a atomic number 1 peroxide pouch, researchers believe the compound could have superior abilities to rescue a senior high school concentration of oxygen directly to the wounded tissue. The combination of Oxycyte gel and H2O2 is believed to be the key to its possible efficacy. The company intends to defer to the FDA a protocol for a proposed clinical probe before the end of the calendar year.
"Unlike the intravenous drug applications programme of Oxycyte in traumatic brain injury, this would be a topical diligence, applied to the skin or to the surface of wounds. So we're hopeful that the clinical review treat would be as a medical twist, which can be shorter and faster than review as a drug," said company chairperson and CEO Chris J. Stern, DBA. "If the safety/efficacy cps is indeed shorter, as I trust it can be, and so it suggests that substantial partnering models could be launched shortly after refuge and efficacy are proved. Sales of ointments, dressings, bandages, etc are counted in the high billions of dollars each twelvemonth. I think that every one of these products could prove to be a candidate to post a anatomy of Oxycyte.
"While I'm excited about this new potential habit for Oxycyte, I know that the big question on our shareholders' minds right now is the status of our Phase IIb protocol for Oxycyte in TBI. We're non going to get into the details of our communications with the FDA. That would not be in the best interests of the company or the process. I'll just say that positive communications are continuing and that when there is news, we'll declare it," said Stern.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and aesculapian devices in the field of atomic number 8 therapeutics and continuous substrate monitoring. The Company has under development a pFC therapeutic atomic number 8 carrier and liquid ventilating system product and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarct, surgery, injury, malignant tumors and diabetes. For further information, visit http://www.oxybiomed.com.
Caution Regarding Forward-Looking Statements
This news release contains certain modern statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include references to potential wound care applications of Oxycyte in treating open wounds, abrasions and george Burns and to expectations that the FDA will permit clinical trials and reviews to be conducted as a medical device rather than a drug. Forward-looking statements in this release also include those that suggest markets in which a injury care edition of Oxycyte could be used and estimates of the accumulative size of those markets. Actual events or results may take issue from the company's expectations. There tin can be no assurance that the FDA will approve a protocol to carry on clinical trials for these applications, that it testament allow examination and review as a medical device, and that if conducted, any clinical trials will be successful or that the FDA will approve use of Oxycyte in any formulation in the uses described in this release. Furthermore, there can be no assurance that if the FDA does approve such uses that the production will compete successfully or that sales at any meaningful levels will be reached. There can be no assurance also that the company will be able to reach or launch whatever partnering agreements to acquire and/or market these applications of Oxycyte. Additional info concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can buoy be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via http://www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intention or duty to update these advanced statements beyond the appointment of this release. This caution is made under the safe harbor provender of the Private Securities Litigation Reform Act of 1995.
Oxygen Biotherapeutics, Inc.
More info
Friday, 5 September 2008
Tuesday, 26 August 2008
Struggling to pay
A poll by Macmillan Cancer Support suggests nearly half of cancer patients in England are being forced to cut back on basic necessities in order to pay for their prescriptions.
Breast cancer survivor Amanda Whetstone says she regularly skips breakfast and lunch to save money to pay for her prescriptions.
Amanda, 45, from Chessington in Surrey, said: "Although my cancer treatment - the surgery, chemotherapy and radiotherapy - has finished, I still need medication.
"As a result of my cancer I'm now on three different drugs. They cost me about �44 a month. That may not sound much to some, but I'm struggling financially.
"I'm now on statutory sick pay because I've been also unwell to work. My income is �360 per month and, quite frankly, I have barely sufficiency money to live on.
"I budget for everything. I don't go out because I can't give to socialise. I can't even invite friends o'er for a meal because I can't afford the food.
"I don't eat breakfast or lunch. The meals I do buy are ones that are on special offer.
"I can't afford fresh fruit or kernel. I know that isn't healthy, simply I simply can't give to buy healthy food."
Amanda said she has as well avoided going for dental and eye checks because she can't pay the bill.
With wintertime approaching, she is too worried about rising fuel costs.
"I have stayed awake at night for hours crying, thinking: 'How can I make this work?'
"Fighting genus Cancer is hard enough without the wicked financial worry that comes with it.
"I feel penalised because I have a disease that the government activity doesn't consider should make me let off from ethical drug charges."
Amanda said she had looked into the choice of remunerative a reduced annual fee of for her prescriptions but aforesaid she could not open to pay the oaf sum of �102.50.
She was surprised to hear that the prescription prepayment certification (PPC) schema, which allows patients to get all the prescription items they need for less than �2 a week, is available by monthly organise debit to help gap the cost of payments.
Alternatively, people world Health Organization have to pay for more than three prescription items in three months can pay three-month PPC of �27.85.
More info
Monday, 30 June 2008
Tuesday, 24 June 2008
Sadus
Artist: Sadus
Genre(s):
Metal: Death,Black
Metal: Thrash
Rock
Discography:
Out For Blood
Year: 2006
Tracks: 14
Elements Of Anger
Year: 1997
Tracks: 10
A Vision Of Misery
Year: 1992
Tracks: 9
Chemical Exposure
Year: 1991
Tracks: 10
Swallowed In Black
Year: 1990
Tracks: 11
Illusions
Year: 1988
Tracks: 10
Part of the original thrash metal scene in the mid to later '80s, San Francisco's Sadus primitively consisted of members Darren Travis on vocals and guitar, Rob Moore on guitar, Steve DiGiorgio on basso, and Jon Allen on drums. The group began when all four members were attendance high school in 1984, and due to the circulation of such demos as 1986's DTP and 1987's Certain Death, the group reinforced a local following. By the terminal of 1988, the band issued a debut full-length on their own, highborn Illusions, produced by Metal Church guitar player John Marshall. This lED to a deal with the metal label Roadrunner Records, which issued Swallowed in Black in 1990; the group supported it a spell opening for Obituary and Sepultura. The following year, DiGiorgio lententide his bass playing talents to the recording of Death's Human record album, which helped introduce Sadus to a wider audience as they toured that same year with Morbid Angel in Europe for the first-class honours degree time.
Further releases followed -- Chemical Exposure and A Vision of Misery -- before the mathematical group leftfield Roadrunner. Shortly thenceforth, DiGiorgio rejoined Death to record their Individual Thought Patterns album, and this time, decided to tour with the banding as Sadus took a give out. In 1997, Sadus reunited to disc a new album for young label Mascot Records, just by this time, Moore had leftfield the grouping. Undeterred, the group carried on as a triad, releasing Elements of Anger (produced by illustrious thrash/death metal producer Scott Burns) in 1998. DiGiorgio has become one of the genre's almost sought-after bassists, as he's played with such other bands as Dragonlord, Autopsy, and Iced Earth. By 2000, it appeared as though Sadus was put on adjudge however over again, as the rhythm method section of DiGiorgio and Allen recognized an invitation to conjoin Testament.
Monday, 16 June 2008
A Stone Temple Suit
The Stone Temple Pilots are singing the legal blues.
Atlantic Records is suing two of the grunge rock band's members, frontman Scott Weiland and drummer Eric Kretz, alleging they...
Saturday, 7 June 2008
Hbo - Former Critic Frank Rich To Help Develop Shows For Hbo
New York Times
Op-Ed columnist Frank Rich is becoming a "creative consultant" to HBO to participate
in the development of new programs. Rich has been a film and TV critic for Time
and a theater critic for the New York Times from 1980-1994. Rich told the
Times today (Thursday) that his role at HBO will be "to bring ideas, to vet
ideas, everything from comedies to documentaries to docudramas."
22/05/2008
See Also
Friday, 6 June 2008
Coldplay Adds L.A. show
Anyone who feared that British pop-rockers Coldplay [ tickets ] would skip over the Los Angeles area during their soon-to-launch US tour can breathe a sigh of relief.New to the group's schedule is a July 15 concert at The Forum in Inglewood, CA. The stop fills a crack in the itinerary for the first leg of the band's North American tour, which gets underway in New York City later this month with a free show at Madison Square Garden, and runs through early August. A second North American leg is set to kick off in late October.
Subscribe to:
Posts (Atom)